193 related articles for article (PubMed ID: 15630593)
41. Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production.
Ghiotto-Ragueneau M; Battifora M; Truneh A; Waterfield MD; Olive D
Eur J Immunol; 1996 Jan; 26(1):34-41. PubMed ID: 8566081
[TBL] [Abstract][Full Text] [Related]
42. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice.
Yadav D; Hill N; Yagita H; Azuma M; Sarvetnick N
Cell Immunol; 2009; 258(2):161-71. PubMed ID: 19497561
[TBL] [Abstract][Full Text] [Related]
43. Activation of murine T cells by bacterial superantigens requires B7-mediated costimulation.
Muraille E; De Smedt T; Thielemans K; Urbain J; Moser M; Leo O
Cell Immunol; 1995 May; 162(2):315-20. PubMed ID: 7538050
[TBL] [Abstract][Full Text] [Related]
44. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death.
Lang S; Atarashi Y; Nishioka Y; Stanson J; Meidenbauer N; Whiteside TL
Cell Immunol; 2000 May; 201(2):132-43. PubMed ID: 10831322
[TBL] [Abstract][Full Text] [Related]
45. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
Karim R; Jordanova ES; Piersma SJ; Kenter GG; Chen L; Boer JM; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Oct; 15(20):6341-7. PubMed ID: 19825956
[TBL] [Abstract][Full Text] [Related]
46. Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules.
Chapoval AI; Zhu G; Chen L
Mol Biotechnol; 2002 Jul; 21(3):259-64. PubMed ID: 12102550
[TBL] [Abstract][Full Text] [Related]
47. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity.
Khoury SJ; Sayegh MH
Immunity; 2004 May; 20(5):529-38. PubMed ID: 15142522
[TBL] [Abstract][Full Text] [Related]
48. Regulation of Immunity by Butyrophilins.
Rhodes DA; Reith W; Trowsdale J
Annu Rev Immunol; 2016 May; 34():151-72. PubMed ID: 26772212
[TBL] [Abstract][Full Text] [Related]
49. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.
Calabrese LH; Caporali R; Blank CU; Kirk AD
J Autoimmun; 2020 Dec; 115():102546. PubMed ID: 32980229
[TBL] [Abstract][Full Text] [Related]
50. The expression, function, and clinical relevance of B7 family members in cancer.
Seliger B; Quandt D
Cancer Immunol Immunother; 2012 Aug; 61(8):1327-41. PubMed ID: 22695874
[TBL] [Abstract][Full Text] [Related]
51. Boosting T cell costimulation in cancer: the possibilities seem endless.
Evans DE; Weinberg AD
Int Rev Immunol; 2003; 22(2):173-94. PubMed ID: 12962274
[TBL] [Abstract][Full Text] [Related]
52. To be or not to be B7.
Zang X; Allison JP
J Clin Invest; 2006 Oct; 116(10):2590-3. PubMed ID: 17016555
[TBL] [Abstract][Full Text] [Related]
53. New battlefields for costimulation.
Martin-Orozco N; Dong C
J Exp Med; 2006 Apr; 203(4):817-20. PubMed ID: 16606678
[TBL] [Abstract][Full Text] [Related]
54. T-cell activation. Two for T.
Guerder S; Flavell RA
Curr Biol; 1995 Aug; 5(8):866-8. PubMed ID: 7583143
[TBL] [Abstract][Full Text] [Related]
55. Improved prediction of prognosis and therapy response for lung adenocarcinoma after identification of DNA-directed RNA polymerase-associated lncRNAs.
Yu J; Lan L; Liu C; Zhu X
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12737-12754. PubMed ID: 37453971
[TBL] [Abstract][Full Text] [Related]
56. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Zibelman M; MacFarlane AW; Costello K; McGowan T; O'Neill J; Kokate R; Borghaei H; Denlinger CS; Dotan E; Geynisman DM; Jain A; Martin L; Obeid E; Devarajan K; Ruth K; Alpaugh RK; Dulaimi EA; Cukierman E; Einarson M; Campbell KS; Plimack ER
Nat Commun; 2023 Jul; 14(1):4513. PubMed ID: 37500647
[TBL] [Abstract][Full Text] [Related]
57. PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade.
Donini C; Galvagno F; Rotolo R; Massa A; Merlini A; Scagliotti GV; Novello S; Bironzo P; Leuci V; Sangiolo D
Br J Cancer; 2023 Oct; 129(9):1409-1416. PubMed ID: 37474722
[TBL] [Abstract][Full Text] [Related]
58. Programmed death-ligand 1 and tumor-infiltrating lymphocytes (TILs) - low TIL density may predict poorer long-term prognosis in T1 laryngeal cancer.
Pakkanen P; Ilmarinen T; Halme E; Irjala H; Koivunen P; Pukkila M; Ventelä S; Almangush A; Birkman EM; Lindgren O; Pohjolainen V; Sjöblom N; Haglund C; Hagström J; Aaltonen LM
Virchows Arch; 2023 Jul; ():. PubMed ID: 37462760
[TBL] [Abstract][Full Text] [Related]
59. Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.
Li Y; Wu B; Hossain MJ; Quagliata L; O'Meara C; Wilkins MR; Corley S; Khachigian LM
J Transl Med; 2023 Jul; 21(1):467. PubMed ID: 37452307
[TBL] [Abstract][Full Text] [Related]
60. Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches.
Yura Y; Hamada M
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
